Dimerix Ltd - Dimerix Announces New Drug Candidate, DMX-700
Dimerix Ltd (ASX:DXB)

Dimerix Announces New Drug Candidate, DMX-700

Published Oct 21, 2019

What happened?


A Larger Pipeline

Dimerix have diversified their drug pipeline by discovering DMX-700 for Chronic Obstructive Pulmonary Disease (COPD).

What is COPD?

COPD is the fourth-leading cause of death in the world and although treatments exist to improve the symptoms of COPD, there is currently no way to slow progression of the condition or cure it. There is a significant unmet need in COPD. In 2016, the Global Burden of Disease Study reported a prevalence of 251 million cases of COPD globally, and it was estimated that 3.17 million deaths were caused by the disease in 2015.

What causes COPD?

The primary cause of COPD is exposure to tobacco smoke (either active smoking or secondary smoke), however is also caused by exposure to indoor and outdoor air pollution, occupational dusts and fumes and long-term asthma.

What was the discovery Dimerix made?

Receptor-HIT has identified a heteromer association between two receptors expressed on the lung. Both of these receptors have been independently implicated in the pathophysiology of COPD, however investigations into each single receptor have provided disappointing results to date. Dimerix anticipates that this is due to the heteromer nature of the receptor and has discovered that simultaneous inhibition of both receptors may significantly improve efficacy.

What is next for DMX-700?

Over the next 12 months Dimerix will conduct further proof of concept studies to perform the value-added verification in support of a robust product development pathway and patent position. DMX-700 is a New Chemical Entity, however the safety profile is well understood. As such, it is anticipated that Dimerix would initiate human clinical studies in less than 2 years.

CEO's summary

Nina Webster CEO of Dimerix Ltd has provided a statement.
Nina Webster
Nina Webster
CEO, Dimerix Ltd

"We have very high hopes for this drug candidate making a real difference in the lives of those suffering from COPD, where there is a significant unmet need. Dimerix continues to assess potential opportunities that fit with the company strategy. We intend to focus on selecting appropriate pipeline candidates within our resource and funding capabilities. All potential opportunities screened are commercially attractive and could result in patient preferred products."

Download Announcement

View this announcement as well as our full profile on the company.

Comments

Share your thoughts about this announcement...

Around the web
DXB kidney disease treatment Phase III trial officially begins
We invested in Dimerix (ASX:DXB) in August for its fully funded Phase III clinical trials treating F...
via finfeed.com
Dimerix (ASX:DXB) receives approvals to start Phase 3 kidney damage trial
Dimerix (DXB) is granted Australian ethics and regulatory approval for its Phase 3 clinical trial i...
via themarketherald.com.au
Late-stage trial for Dimerix's investigative COVID-19 treatment
Dimerix is partnering with the NHMRC Clinical Trials Centre at the University of Sydney to e...
via biotechdispatch.com.au
Powered by  
  • Company
    Dimerix Ltd
  • Website
  • Sector
    Biotechnology
  • Industry
    Biotechnology
  • Code
    ASX:DXB
  • Socials
View Dimerix Ltd's Profile

How do I invest?

Considering investing in Dimerix Ltd?
Here's how to get started.
Low Cost Brokerage ASX Cheapest ASX Trading Platform
  1. 1

    Create account

    Open an account with an online broker of your choice. If you do not have an existing broker, consider Mawson Graham's A$9.50 flat fee platform.

    Sign up now »
  2. 2

    Search for ASX:DXB

    On your online investment platform search for the stock ticker code ASX:DXB to bring up the company's shares.

  3. 3

    Buy shares

    Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.

Up